CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
Gerard Walls(Queen's University Belfast), Alastair Greystoke(Newcastle University), Tom Haswell(University of Oxford), Chris Twelves(University of Leeds), Stephen Harrow(Beatson West of Scotland Cancer Centre), Crispin T. Hiley(The Francis Crick Institute), Fiona Collinson(St James's University Hospital), Rachel Phillip(University of Leeds), Alexandra Gilbert(St James's University Hospital), Jamie B. Oughton, David Sebag‐Montefiore(University of Leeds), Anthony J. Chalmers(Beatson West of Scotland Cancer Centre), Sarah Brown(University of Leeds), Katrina Walker(University of Leeds), Martin Förster, Matthew Krebs(Christie's), Gerard G. Hanna(Belfast Health and Social Care Trust), Samantha Hinsley(University of Leeds), Geraldine Murden(University of Leeds), Anderson J. Ryan(University of Oxford), Robin Young(Weston Park Cancer Centre), Nicola Hannaway(Newcastle University), Ahmed Salem(The University of Texas MD Anderson Cancer Center), Paul Shaw(Velindre Cancer Centre), Corinne Faivre‐Finn(University of Manchester)
Cited by 34
Related Papers
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k